Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02694978 · ClinicalTrials.gov registry record · Phase 3
A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
A Phase 3 study, sponsored by AMAG Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,014
- Enrollment target
NCT02694978 is a Phase 3 study that has completed, run by AMAG Pharmaceuticals. The registered enrollment target is 2,014 participants.
The verdict
NCT02694978, a Phase 3 study, has completed, sponsored by AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,014 participants
- Enrollment target
Study Summary
To evaluate the safety of 1.020 grams (g) of intravenous (IV) ferumoxytol compared to 1.500 g of IV ferric carboxymaltose (FCM).
Interventions
- DRUG Ferumoxytol
- DRUG FCM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,014 participants |
| Start Date | 2016-02-29 |
| Est. Completion | 2017-07-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02694978
The ClinicalTrials.gov registry entry for NCT02694978 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,014 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AMAG Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferumoxytol is the first listed.
NCT02694978 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02694978 about?
NCT02694978 is a clinical study titled "A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)". To evaluate the safety of 1.020 grams (g) of intravenous (IV) ferumoxytol compared to 1.500 g of IV ferric carboxymaltose (FCM).
What is the current status of trial NCT02694978?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,014 participants. The study started on 2016-02-29. Estimated completion is 2017-07-17.
What interventions are being tested in trial NCT02694978?
The interventions under investigation include: Ferumoxytol (DRUG), FCM (DRUG).
Who is sponsoring clinical trial NCT02694978?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.